A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs ADVAX (Primary) ; Influenza A virus H5N1 vaccines (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Vaxine
- 15 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 08 Dec 2015 Planned End Date changed from 1 Jan 2018 to 1 Dec 2016, according to ClinicalTrials.gov record.